In humans, decreased circulating OXT levels have been recorded in individuals with obesity or diabetes, and OXT administration is currently being explored as a treatment for obesity-related comorbidities43 (Supplementary Data 4). Here, OXT is linked to obesity due to melanocortin 4 receptor deficiency.